FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.

Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.

Michael Lattanzi discusses treatment plans and research in the community.

Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries

David McDermott discusses melanoma and renal data. We never get to bladder or lung.

Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer

Neeraj Agarwal addresses the issues raised at the meeting.

Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005